Successful use of Tocilizumab in a patient with nephrotic syndrome due to a rapidly progressing AA amyloidosis secondary to latent tuberculosis
2011; Taylor & Francis; Volume: 18; Issue: 4 Linguagem: Inglês
10.3109/13506129.2011.613962
ISSN1744-2818
AutoresCésar Magro‐Checa, Antonio Navas-Parejo Casado, Elena Borrego-García, Enriqué Raya-Álvarez, José Luis Rosales-Alexander, Juan Salvatierra, Trinidad Caballero-Morales, Mercedes Gómez‐Morales,
Tópico(s)Pancreatitis Pathology and Treatment
ResumoAA (secondary) amyloidosis is one of the most severe and uncommon complications of several rheumatic disorders and chronic infections such as tuberculosis (TB). Successful treatment depends on the control of the underlying inflammatory process, what can lead to an improvement or a regression in organ dysfunction. If the disorder persists, it has been reported in some cases of AA amyloidosis secondary to rheumatic diseases, that the use of biologic therapy is so far the only opportunity to reduce the development of AA amyloidosis and to reverse established deposits. We report herein a case of a latent TB infection complicated by a life-threatening AA amyloidosis presented as nephrotic syndrome. After an adequate antituberculostatic treatment, AA amyloidosis remained active and Tocilizumab (TCZ) was started with a dramatic resolution of the proteinuria, stabilization of the amyloid deposits and improvement in general condition.
Referência(s)